Efficacious Treatment Of Nsclc And Predictive Clinical Marker Of The Responsiveness Of A Tumour To A Treatment
Patent No. EP2994125 (titled "Efficacious Treatment Of Nsclc And Predictive Clinical Marker Of The Responsiveness Of A Tumour To A Treatment") was filed by Boehringer Ingelheim on May 8, 2014. The application was issued on Aug 1, 2018.
Patent Summary
Designing an individual therapy for a subject suffering from non-small cell lung cancer (NSCLC) as well as to a clinical indicator (hereinafter designated as clinical marker) useful as predictive variable of the responsiveness of a NSCLC tumour to a treatment. The therapy includes treatment with a vascular endothelial growth factor inhibitor or with a vascular endothelial growth factor receptor inhibitor.
Patent Family
Patent Oppositions (4)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP2994125
- Application Number
- EP14721905A
- Filing Date
- May 8, 2014
- Status
- Revoked
- Mar 6, 2020
- Publication Date
- Aug 1, 2018
- External Links
- Slate, Register , Google Patents